Oxidative stress, due to free radical accumulation and age-related inflammation, is one of the well-known mechanisms involved in Alzheimer’s disease; luckily, this is a modifiable risk factor and we can eat foods with antioxidant and anti-inflammatory properties to counter it. A recent study found that grapes may protect against Alzheimer’s disease. Grapes contain a group of compounds called polyphenols that promote antioxidant and anti-inflammatory actions; one particular polyphenol, called resveratrol, is especially important to brain health.
Human muscles begin to deteriorate after only a few days of bed rest. In fact, previous studies have shown that it only takes one week in an intensive care unit (ICU) for muscles to weaken to the point of difficulty or inability to walk after being discharged; this affects recovery, length of hospital stay, and the transition back home. To counter this problem, McMaster University and St. Joseph’s Healthcare have teamed up to run a cycle therapy (CT) program; the CT trial is the basis of their most recent pilot study.
The McMaster Optimal Aging Portal, developed in 2014, is a highly successful online resource for aging. The Portal consists of blog posts written by experts, ratings for other web-based health resources, and accessible summaries of recent aging studies. It is set apart from other online health resources because it includes only high-quality research and explains it in an accessible way, with the goal of empowering seniors to make informed health decisions. McMaster hopes to include research-based information concerning the social aspects of aging by 2017.
A new study discovered that blocking a receptor in the brain that regulates immune cells could prevent some changes to memory and behaviour observed in Alzheimer’s disease. This study adds to evidence that inflammation in the brain plays a role in the development of Alzheimer’s disease
The Dementia Discovery Fund, established last year with support from the U.K. government and several of the world’s largest pharmaceutical companies, aims to create at least one breakthrough dementia treatment by 2025. The fund has made its first investment of $29.5 million to San Francisco-based Alector LLC.